CARD9 anticorps (AA 450-500)

N° du produit ABIN7452807

Cet anticorps anti-CARD9 est un anticorps Lapin Polyclonal détectant CARD9 dans WB et IP. Adapté pour Humain.

Aperçu rapide pour CARD9 anticorps (AA 450-500) (ABIN7452807)

Antigène: CARD9 (Caspase Recruitment Domain Family, Member 9 (CARD9))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp CARD9 est non-conjugé

Application: Western Blotting (WB), Immunoprecipitation (IP)

Détail du produit anti-CARD9 anticorps

Épitope: AA 450-500

Fonction: Rabbit anti-CARD9 Antibody, Affinity Purified

Purification: Affinity Purified

Immunogène: between AA 450 and 500

Isotype: IgG

Information d'application

Indications d'application:

IP: 50-100 μL/mg lysate

WB: 1:10,000 - 1:25,000

Restrictions: For Research Use only

Stockage

Concentration: 1000 μg/mL

Buffer: Tris-citrate/phosphate buffer, pH 7 to 8 containing 0.09 % Sodium Azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Date de péremption: 12 months

Détails sur CARD9

Antigène: CARD9 (Caspase Recruitment Domain Family, Member 9 (CARD9))

Autre désignation: CARD9

Sujet: Background: CARD9 is an adapter protein that plays a key role in innate immune response to a number of intracellular pathogens, such as C.albicans and L.monocytogenes. Is at the crossroads of ITAM-tyrosine kinase and the Toll-like receptors (TLR) and NOD2 signaling pathways. Probably controls various innate immune response pathways depending on the intracellular pathogen. In response to L.monocytogenes infection, acts by connecting NOD2 recognition of peptidoglycan to downstream activation of MAP kinases (MAPK) without activating NF-kappa-B. Also involved in activation of myeloid cells via classical ITAM-associated receptors and TLR: required for TLR-mediated activation of MAPK, while it is not required for TLR-induced activation of NF-kappa-B (By similarity). Controls CLEC7A (dectin-1)-mediated myeloid cell activation induced by the yeast cell wall component zymosan, leading to cytokine production and innate anti-fungal immunity: acts by regulating BCL10-MALT1-mediated NF-kappa-B activation pathway. Activates NF-kappa-B via BCL10. In response to the hyphal form of C.albicans, mediates CLEC6A (dectin-2)-induced I-kappa-B kinase ubiquitination, leading to NF-kappa-B activation via interaction with BCL10. In response to fungal infection, may be required for the development and subsequent differentiation of interleukin 17-producing T helper (TH-17) cells. [taken from the Universal Protein Resource (UniProt) Q9H257].+B3:B11

ID gène: 64170

UniProt: Q9H257

Pathways: Activation of Innate immune Response